Nu Skin Enterprises (NYSE: NUS ) fell an additional 10% on Friday after Thursday's plummet of 29%, following a report that the Chinese government will investigate the company as a possible pyramid scheme. Nu Skin is heavily reliant on the Chinese market for growth, so such an investigation will affect the stock negatively, even if nothing is found.
In this video, Fool health-care analyst David Williamson looks at Nu Skin and its relationship with the Chinese market. He tells investors just how strong of an impact this investigation could have on the stock, and whether this week's precipitous fall means a buying opportunity, or that it's time to get out.
Looking for more interesting plays in health care?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.